Boehringer Ingelheim (France)

Timing of antifibrotic therapy and prognosis in idiopathic pulmonary fibrosis: real-world evidence from the French Colibri-ILD SNDS database

According to the French 2022 National guideline, antifibrotic therapy should be initiated as soon as a diagnosis of idiopathic pulmonary fibrosis (IPF) is made, taking into account the individual assessment of the expected benefit and risks of treatment. However, in practice, tre...

Recent Advancesin Nonprecious Metal Catalysis

Abstract As part of a precompetitive alliance, Boehringer Ingelheim, Pfizer, and AbbVie publish a quarterly review series dedicated to recent advances in nonprecious metal catalysis (NPMC). By informing synthetic chemists about noteworthy developments in NPMC, these reviews aim t...